Dr. Satish Wagh, Chairman & MD, Supriya Lifescience speaks to Express Pharma on the company’s strategy to achieve a turnover of INR 1000 crore within the next five years, and how PLI schemes are helping pharma manufacturers to backward integrate. India is now being seen as a focused pharma manufacturer, according to Dr Wagh and explains how these moves will ensure that the pharma sector will be a major contributor to India’s economy.